10,000 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Acquired by Entropy Technologies LP

Entropy Technologies LP bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $320,000.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of SpringWorks Therapeutics by 8.2% in the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock valued at $321,373,000 after purchasing an additional 492,783 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock worth $202,318,000 after acquiring an additional 1,333,892 shares during the period. Maverick Capital Ltd. raised its stake in shares of SpringWorks Therapeutics by 36.3% in the second quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company’s stock valued at $97,962,000 after acquiring an additional 691,894 shares in the last quarter. Fiera Capital Corp boosted its holdings in SpringWorks Therapeutics by 41.4% in the second quarter. Fiera Capital Corp now owns 1,297,302 shares of the company’s stock valued at $48,869,000 after purchasing an additional 380,027 shares during the period. Finally, Duquesne Family Office LLC acquired a new position in SpringWorks Therapeutics during the 2nd quarter worth $38,475,000.

SpringWorks Therapeutics Stock Down 0.3 %

Shares of SWTX opened at $36.45 on Friday. The company has a market capitalization of $2.71 billion, a price-to-earnings ratio of -9.39 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 52-week low of $19.61 and a 52-week high of $53.92. The stock has a 50 day moving average price of $32.70 and a 200 day moving average price of $37.07.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.03. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The firm had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. During the same period last year, the firm posted ($1.27) EPS. The company’s revenue was up 4810.0% on a year-over-year basis. On average, equities analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SWTX shares. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a research report on Thursday, November 7th. HC Wainwright decreased their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. increased their price objective on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $68.17.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.